U's patent no 11 357 782 treprostinil?

What does patent 11 357 782 cover?
Patent 11 357 782 protects a treprostinil formulation that offers improved stability and delivery characteristics over existing products. The claims focus on the chemical composition, dosage form, and method of administration that enhance therapeutic efficacy or reduce side‑effects.

Who owns this patent?
The applicant is the U company, which has been active in developing prostanoid therapies. The grant to U indicates that the company has secured exclusive rights to the described treprostinil innovations.

When will the patent expire?
A U.S. patent issued in 2024 typically has a 20‑year term from the earliest filing date. If the filing was in 2004, the patent would expire around 2024; if it filed later, expiry will shift accordingly. The exact expiration can be checked on DrugPatentWatch.

Can a biosimilar enter the market before the patent expires?
No. A biosimilar must wait until the original patent and related exclusivities lapse. If the patent is still active, regulatory agencies will not approve a biosimilar for the same therapeutic indication.

What are the key claims?
The patent claims a treprostinil compound with a novel excipient mix that increases bioavailability. It also claims a specific dosage range that balances efficacy and safety, and a method of using the formulation for pulmonary arterial hypertension.

How does this affect patients?
Patients using treprostinil may see limited options until the patent expires, as only the original product and licensed partners can market it. After expiry, additional manufacturers could offer lower‑cost alternatives, potentially expanding access.

Where to find the full patent text?
The complete document, including claims and specifications, is available on DrugPatentWatch.com. Check the site for the official patent filing, status, and any legal updates.
[1] https://drugpatentwatch.com/patents/11357782

Sources
[1] https://drugpatentwatch.com/patents/11357782